1. Home
  2. |Insights
  3. |DOD Required to Reimburse Pension Cost Deficit

DOD Required to Reimburse Pension Cost Deficit

Client Alert | 1 min read | 07.18.12

In Raytheon Co. v. U.S. (July 16, 2012), the Court of Federal Claims awarded Raytheon $59.2 million for the "segment closing adjustment" required by CAS 413 to cover unreimbursed pension costs in two business units sold by Raytheon in 2001 and 2002, finding on virtually every contested issue that the calculation of Raytheon's expert actuarial witness was reasonable and that the government's expert had not carried the burden of proving that the Raytheon calculations were noncompliant with CAS. In addition, effectively reversing a prior decision in Raytheon Co. v. U.S., 96 Fed. Cl. 548 (2011), and addressing an issue that will have potentially broader implications beyond CAS 413 segment closing cases, the court found that Raytheon's agreement to the standard form novation language under which the seller "waives" all claims against the Government on novated contracts did not result in a waiver of the CAS 413 segment closing claim on several grounds.

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...